Long-term retrospective study on the progression of prediabetes to diabetes mellitus in transfusion-dependent β-thalassemia (β-TDT) patients: The experience in Oman and Italy: From prediabetes to diabetes mellitus in thalassemia

Long-term retrospective study on the progression of prediabetes to diabetes mellitus in transfusion-dependent β-thalassemia (β-TDT) patients: The experience in Oman and Italy

From prediabetes to diabetes mellitus in thalassemia

Authors

  • Vincenzo De Sanctis Quisisana Hospital, Ferrara https://orcid.org/0000-0002-6131-974X
  • Shahina Daar Department of Hematology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Sultanate of Oman
  • Ashraf Soliman Department of Pediatrics, Division of Endocrinology, Hamad General Hospital, Doha, Qatar
  • Saveria Campisi UOSD Thalassemia, Umberto I° Hospital, Siracusa, Italy
  • Ploutarchos Tzoulis Department of Diabetes and Endocrinology, Whittington Hospital, University College London, London, UK

Keywords:

β-thalassemia major, prediabetes, diabetes,OGTT, HOMA2- IR, HOMA2-% β, HOMA2-%S.

Abstract

Background: Prediabetes in transfusion-dependent β-thalassemia (β-TDT) patients is a significant risk factor for development of diabetes mellitus (DM), with increasing incidence with age. Objectives: This retrospective study aimed to compare the progression from prediabetes to DM in β-TDT patients who initiated iron chelation therapy (ICT) before age 6 and between ages 6 and 10. Additionally, we sought to characterize the trajectories of fasting and post-glucose load insulin sensitivity and secretion (HOMA2-%S and HOMA2-% β) in a β-TDT subgroup, monitored annually for four years preceding DM diagnosis. Research Design and Methods: We retrospectively reviewed annual oral glucose tolerance test (OGTT) data for 18 β-TDT patients from Oman and Italy, from the onset of prediabetes to DM diagnosis. Results: The mean age at prediabetes diagnosis was 17.5 ± 4.2 years, and at DM diagnosis was 21.6 ± 5.2 years. A direct correlation was observed between the age at prediabetes and DM diagnosis (r: 0.6925, P: 0.0014). Three years before DM diagnosis, a notable increase in baseline, 1-hour, and 2-hour post-load plasma glucose levels during OGTT was observed, alongside a decrease in HOMA2-% β. Conclusions: Elevated 1-hour post-load plasma glucose levels and a declining HOMA2-% β during the transition to DM are indicative markers for identifying β-TDT patients with high likelihood for imminent progression to DM.

References

Nidhi Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes. 2015; 6(2): 296–303. doi: 10.4239/wjd.v6.i2.296.

Yip WCY, Sequeira IR, Plank LD, Poppitt SD. Prevalence of pre-diabetes across ethnicities: a review of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) for classification of Dysglycaemia. Nutrients. 2017;9.1273. doi: 10.3390/nu9111273.

De Sanctis V, Daar S, Soliman AT, Tzoulis P, Yassin MA, Kattamis C. Evolution of combined impaired fasting glucose and impaired glucose tolerance in β-thalassemia major: Results in 58 patients with a mean 7.7- year follow-up. Acta Biomed. 2022; 93(3): e2022242. doi:10.23750/abm. v93i3.12825.

De Sanctisv, Soliman A, Tzoulis P, et al. Clinical characteristics, biochemical parameters and insulin response to oral glucose tolerance test (OGTT) in 25 transfusion dependent β-thalassemia (TDT) patients recently diagnosed with diabetes mellitus (DM). Acta Biomed 2021;92 (6): e2021488.doi:10.23750/ abm.v92i6.12366.

De Sanctis V, Daar S, Soliman AT. Screening for glucose dysregulation in β-thalassemia major (β-TM): An update of current evidences and personal experience. Acta Biomed. 2022;93(1): e2022158. doi: 10.23750 /abm.v93i1.12802.

American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes - 2020. Diabetes Care. 2020; 43(Suppl.1): S14-S31.doi:10.2337/dc20-S002.

WHO (World Health Organ.). Definition and diagnosis of diabetes mellitus and intermediate. Rep, WHO, Geneva. 2006. www.who.int/diabetes/publications.

Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279–90. doi: 10.1016/S0140-6736(12)60283-9.

Hostalek U. Global epidemiology of prediabetes - present and future perspectives. Clin Diabetes Endocrinol. 2019; 5: 5. doi:10.1186/s40842-019-0080-0.

Vaccaro O, Ruffa G, Imperatore G, et al. Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care. 1999;22:1490–3. doi:10.2337/diacare.22.9.1490.

De Sanctis V, Soliman AT, Elsedfy H, et al. Growth and endocrine disorders in talassemia. The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab. 2013;17:8-18. doi:10.4103/2230-8210.107808.

Chen Z, Shao L, Jiang M, Ba X, Ma B, Zhou T. Interpretation of HbA1c lies at the intersection of analytical methodology, clinical biochemistry and hematology (Review). Exp Ther Med. 2022; 24(6):707. doi: 10.3892/ etm.2022.11643.

Gomber S, Bagaria A, Madhu SV, Dewan P. Glucose Homeostasis Markers in Beta-Thalassemia. J Pediatr Hematol Oncol. 2018; 40(7):508-10. doi:10.1097/MPH0000000000001161.

De Sanctis V, Soliman AT, Daar S, Tzoulis P, Kattamis C. Can we predict incipient diabetes mellitus in patients with β-transfusion dependent thalassemia (β-TDT) referred with a history of prediabetes? Mediterr J Hematol Infect Dis. 2023 (accepted for publication).

Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocr Metab. 2015;19:160-4. doi:10.4103/2230-8210.146874.

Cooper GR. Methods for determining the amount of glucose in blood. CRC Crit Rev Clin Lab Sci. 1973;4:101–45.doi:10.3109/10408367309151554.

Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia.1985; 28: 412–9. doi:10.1007/BF00280883.

Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27: 1487–95. doi:102337/diacare.27.6.1487.

Alder R, Roesser EB. Introduction to probability and statistics. WH Freeman and Company Eds. Sixth Edition. San Francisco (USA), 1975.PMID:1674139.

De Sanctis V, Soliman AT, Daar S, et al. and International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescence Medicine (ICET-A). Retrospective observational studies: Lights and shadows for medical writers. Acta Biomed. 2022;93(5):e2022319. doi:10.23750/ abm.v93i5.13179.

Farmakis D, Porter J, Taher A, Cappellini MD, Angastiniotis M, Eleftheriou A. 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. Hemasphere.2022;6(8):e732. doi: 10.1097/HS9.0000000000000732.

Cappellini MD, Farmakis D, Porter J, et al. Guidelines for the Management of Transfusion Dependent Thalassaemia. TIF Publication (4th edition – Version 2.0).2021.

Płaczkowska S, Pawlik-Sobecka L, Kokot I, Piwowar A. Estimation of reference intervals of insulin resistance (HOMA), insulin sensitivity (Matsuda), and insulin secretion sensitivity indices (ISSI-2) in Polish young people. Ann Agric Environ Med. 2020;27(2):248–54. doi:10.26444/aaem/109225.

Romo-Romo A, Aguilar-Salinas CA, Gomez-Diaz, et al. Validity and reliability of simple surrogate indexes to evaluate beta-cell function and insulin sensitivity. Rev Med Chile. 2022;150: 1458-66. doi:10.4067/S0034-98872022001101458.

Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contribution of B-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29: 1130–9. doi: 10.2337/dc05-2179.

Berdoukas V, Nord A, Carson S, et al. Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age. Am J Hematol. 2013;88€:283–5. doi:10.1002/ajh. 23545.

Susanah S, Idjradinata PS, Sari NM, et al. Time to start delivering iron chelation therapy in newly diagnosed severe β-thalassemia. Biomed Res Int. 2020; 2020: 8185016. doi: 10.1155/2020/8185016.

Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med. 2015:6:197–209. doi:10.2147/JBM.S72463.

Elalfy MS, Adly A, Awad H, Tarif Salam M, Berdoukas V, Tricta F. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial. Am J Hematol. 2018;3(2):262-8. doi:10.1002/ajh.24966.

Downloads

Published

28-02-2024

Issue

Section

HEMOGLOBINOPATHIES

How to Cite

1.
Long-term retrospective study on the progression of prediabetes to diabetes mellitus in transfusion-dependent β-thalassemia (β-TDT) patients: The experience in Oman and Italy: From prediabetes to diabetes mellitus in thalassemia . Acta Biomed [Internet]. 2024 Feb. 28 [cited 2024 May 20];95(1):e2024050. Available from: https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/15525

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 > >>